TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Faces Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endometrial pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Day time ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of participants with treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with treatment-emergent adverse events (TEAEs) leading to withdrawal from the study
Endpoint domain: Adverse events/effects
Primary endpoint: Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Score in Motor Examination (ME) of the Unified MSA Rating Scale (UMSARS-ME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Adverse Events Graded per NCI CTCAE v4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of time on Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intracranial progression free survival at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Medication Adherence-pill Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social and Occupational Functioning Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Patients Surviving Without Relapse/Exacerbation
Endpoint domain: Mortality/survival
Primary endpoint: Opiate and cocaine craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced Venous Thromboembolism Event or VTE-related Death
Endpoint domain: Mortality/survival
Primary endpoint: Time-to-first Occurrence of VTE or VTE-related Death
Endpoint domain: Mortality/survival
Primary endpoint: Concentration of Uric Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Nitrite / Nitrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major Pathological Response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Low Dose Topical Steroid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief at amputation sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Documentation of characteristics of patients with acute STEMI or NSTEMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of days on mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of tDCS associated side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in outbreak frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to DTM-SCS Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who completed HIV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who accepted a rapid health screening/HIV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction degree
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and specificity of sentinel lymph node frozen section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Unilateral or bilateral sentinel lymph node detection rate by indocyanine green
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of adapted changes in induction technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Obstructive Sleep Apnea (OSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cmax of perampanel tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of perampanel tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) of perampanel tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of Prevenar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of Hypofractionated Stereotactic Radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Knee minimum joint space width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration Troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of somatic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grade 2 and/or 3 fibrosis after radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year Invasive Disease-Free Survival (IDFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability of Contraloid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve (AUC) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Minimal Residual Disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of lymph collected by the drain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of a surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Stabilization of vaginal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive diagnostic scale values
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in neuropsychologic diagnostic scale values
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Consistency of the respiratory pattern during imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Consistency of the respiratory pattern during radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Motion of the tumor and normal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissular resaturation speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VRS pain score on passive movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of allo SCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Suction Electrocautery Time Required for Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pressure Ulcer Presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Participants Who Attain Inactive Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Reduction in Wound Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pressure Ulcer Score for Healing (PUSH) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum surfactant protein D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome measure (pain scores, sedation, nausea, pruritus, respiratory rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: respiratory inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: histological resolution of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worsening of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with normotensive systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum vitamin B12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum methylmalonic acid (MMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean urine concentration of MB-102
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to port complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Analgesic success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical quality based on pathological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of P2X7 Receptor Occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time added to standard TSS procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Completion Rate for Randomised Treatment Phase
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Ixazomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neurochemical peak area ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative refraction measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: neural function deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Meal triglyceride (TG) absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra Ocular Pressure Fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Success of first intubation attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Change in the Average Daily Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Tmax - Time of Occurrence of Cmax of Levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic and parasitological cure with no recrudescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Refractive error changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of MK3475 associated with Metronomic Cyclophosphamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Brain death
Endpoint domain: Mortality/survival
Primary endpoint: Change in ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Toenails Attaining 3 Millimeters (mm) or More of Clear Nail Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Millimeters (mm) of Clear Nail Bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in End Diastolic Diameter of Left Ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lung Cancer Recurrence or Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Child-Reported Health Related Quality of Life-School Functioning Subscale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in FEV1 at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in FEV1 at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Estimated amount of intraoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Empowerment evaluation scale assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL and +/- 15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distribution volume of cannabinoid 1 receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Kaufman Test of Educational Achievement score (KTEA-3)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: intraepidermal nerve fiber density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Thrombolysis success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV dysfunction prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Congenital Heart Disease Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricle Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients utilizing the app
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: tumor SUVmax value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Drug Concentration in Plasma After Multiple Dose (Cmax,md) for Refametinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Response During Phase 2 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Surgical Site Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neurosensory Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients With Tracheal Bacterial Colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nonfatal vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Site repair grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extra renal replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Severity of Alcohol Withdrawal Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchitis Severity Total Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of AE reporting for safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of SAE reporting for safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction assessed by Ocular Surface Disease Index (OSDI) questionnaires for safety and tolerability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of Life Inventory
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: KDQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain scores on the numeric rating scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LH Pulse Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Steady State Amount of Glucose Metabolized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Corrected distance visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision-related quality of life impairment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life determination: SHAQ-DI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Agreement between model derived diagnosis and clinical diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of clinical manifestations of GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite Efficacy Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Function Measured by cGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Hemostasis at the Target Bleeding Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: patient adherence to standard of care eccentric exercise regimens
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Positive predictive value of screening test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pO2 Levels (in mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of Engrailed-2 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Worth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical Activity - Accelerometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Pharmacodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (complete and partial responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Warfarin Knowledge Level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment response correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Staging of bladder tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to First Post-visit Drinking Day
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to First Post-visit Heavy Episodic Drinking Day
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Who Achieved at Least 20% Improvement in ACR20 Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in HAQ-DI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uterine contractions measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological and non-hematological toxicity rates
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in bone mineral density of the lumbar spine (L2-L4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety of HBO Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical and radiographical success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory rate predicting mortality
Endpoint domain: Mortality/survival
Primary endpoint: Blood oxygen saturation level predicting mortality
Endpoint domain: Mortality/survival
Primary endpoint: Core temperature predicting mortality
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from death at 30 days post-procedure
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from Target Lesion Revascularization (TLR) and/or Target Vessel Revascularization (TVR) at 6 months post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of Duvortuxizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linkage to HIV care within 1 month of HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention in care 12 months after testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention